Feb. 4 at 3:32 AM
$DFTX
What I like about Definium from a fundamentals standpoint…
They’ve got over
$500M on hand, so this isn’t some tiny biotech. It’s been seriously funded to get through the FDA process.
Their Phase 2 results were strong, and Phase 3 is built off that data instead of starting from scratch.
They received FDA Breakthrough Therapy status, which speeds things up and usually improves approval odds since the FDA is more involved.
This would be first in class, not just another SSRI. Different mechanism, faster onset, and potentially better long term outcomes instead of people staying on daily meds forever.
The market is massive depression and treatment-resistant depression are tens of billions a year, so even a small share is meaningful.
And if Phase 3 hits, this becomes a prime buyout target for Big Pharma first in class, late-stage, and in a huge market. That alone could justify a much higher valuation.
Not risk free, but this risk is worth the reward.
